BACKGROUND: The efficacy of bed covers that are impermeable to house dust mites has been disputed. AIM: The aim of the present study was to investigate whether the combination of 'house dust mite impermeable' covers and a self-management plan, based on peak flow values and symptoms, leads to reduced use of inhaled corticosteroids (ICS) than self-management alone. DESIGN OF STUDY: Prospective, randomised, double blind, placebo-controlled trial. SETTING:Primary care in a south-eastern region of the Netherlands. METHOD:Asthma patients aged between 16 and 60 years with a house dust mite allergy requiring ICS were randomised to intervention and placebo groups. They were trained to use a self-management plan based on peak flow and symptoms. After a 3-month training period, the intervention commenced using house dust mite impermeable and placebo bed covers. The follow-up period was 2 years. Primary outcome was the use of ICS; secondary outcomes were peak expiratory flow parameters, asthma control, and symptoms. RESULTS:One hundred and twenty-six patients started the intervention with house dust mite impermeable or placebo bed covers. After 1 and 2 years, significant differences in allergen exposure were found between the intervention and control groups (P<0.001). No significant difference between the intervention and control groups was found in the dose of ICS (P = 0.08), morning peak flow (P = 0.52), peak flow variability (P = 0.36), dyspnoea (P = 0.46), wheezing (P = 0.77), or coughing (P = 0.41). There was no difference in asthma control between the intervention and control groups. CONCLUSION: House dust mite impermeable bed covers combined with self-management do not lead to reduced use of ICS compared with self-management alone.
RCT Entities:
BACKGROUND: The efficacy of bed covers that are impermeable to house dust mites has been disputed. AIM: The aim of the present study was to investigate whether the combination of 'house dust mite impermeable' covers and a self-management plan, based on peak flow values and symptoms, leads to reduced use of inhaled corticosteroids (ICS) than self-management alone. DESIGN OF STUDY: Prospective, randomised, double blind, placebo-controlled trial. SETTING: Primary care in a south-eastern region of the Netherlands. METHOD:Asthmapatients aged between 16 and 60 years with a house dust miteallergy requiring ICS were randomised to intervention and placebo groups. They were trained to use a self-management plan based on peak flow and symptoms. After a 3-month training period, the intervention commenced using house dust mite impermeable and placebo bed covers. The follow-up period was 2 years. Primary outcome was the use of ICS; secondary outcomes were peak expiratory flow parameters, asthma control, and symptoms. RESULTS: One hundred and twenty-six patients started the intervention with house dust mite impermeable or placebo bed covers. After 1 and 2 years, significant differences in allergen exposure were found between the intervention and control groups (P<0.001). No significant difference between the intervention and control groups was found in the dose of ICS (P = 0.08), morning peak flow (P = 0.52), peak flow variability (P = 0.36), dyspnoea (P = 0.46), wheezing (P = 0.77), or coughing (P = 0.41). There was no difference in asthma control between the intervention and control groups. CONCLUSION: House dust mite impermeable bed covers combined with self-management do not lead to reduced use of ICS compared with self-management alone.
Authors: M J Colloff; J Ayres; F Carswell; P H Howarth; T G Merrett; E B Mitchell; M J Walshaw; J O Warner; J A Warner; A A Woodcock Journal: Clin Exp Allergy Date: 1992-09 Impact factor: 5.018
Authors: T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; O Selroos; A Sovijärvi Journal: N Engl J Med Date: 1994-09-15 Impact factor: 91.245
Authors: T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos Journal: N Engl J Med Date: 1991-08-08 Impact factor: 91.245
Authors: S G Cloosterman; T R Schermer; I D Bijl-Hofland; S Van Der Heide; B Brunekreef; F J Van Den Elshout; C L Van Herwaarden; C P Van Schayck Journal: Clin Exp Allergy Date: 1999-10 Impact factor: 5.018
Authors: H A Kerstjens; P L Brand; M D Hughes; N J Robinson; D S Postma; H J Sluiter; E R Bleecker; P N Dekhuijzen; P M de Jong; H J Mengelers Journal: N Engl J Med Date: 1992-11-12 Impact factor: 91.245
Authors: E Dompeling; C P van Schayck; P M van Grunsven; C L van Herwaarden; R Akkermans; J Molema; H Folgering; C van Weel Journal: Ann Intern Med Date: 1993-05-15 Impact factor: 25.391
Authors: A Lahdensuo; T Haahtela; J Herrala; T Kava; K Kiviranta; P Kuusisto; E Perämäki; T Poussa; S Saarelainen; T Svahn Journal: BMJ Date: 1996-03-23
Authors: Harris K S Hui; Tin Sum Li; Whitney L W Lo; Andy K C Kan; Shi Yeung Ho; Winnie Y W Yeung; Jane C Y Wong; Valerie Chiang; Birgitta Y H Wong; Philip H Li Journal: Allergo J Int Date: 2022-07-07
Authors: Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh Journal: J Allergy Clin Immunol Date: 2020-12 Impact factor: 10.793
Authors: Alvaro A Cruz; Adelmir Souza-Machado; Rosana Franco; Carolina Souza-Machado; Eduardo V Ponte; Pablo Moura Santos; Maurício L Barreto Journal: World Allergy Organ J Date: 2010-04-23 Impact factor: 4.084